Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Making sense of antisense.
Vidal L, Blagden S, Attard G, de Bono J. Vidal L, et al. Among authors: attard g. Eur J Cancer. 2005 Dec;41(18):2812-8. doi: 10.1016/j.ejca.2005.06.029. Epub 2005 Nov 9. Eur J Cancer. 2005. PMID: 16289851 Review.
Update on tubulin-binding agents.
Attard G, Greystoke A, Kaye S, De Bono J. Attard G, et al. Pathol Biol (Paris). 2006 Mar;54(2):72-84. doi: 10.1016/j.patbio.2005.03.003. Pathol Biol (Paris). 2006. PMID: 16545633 Review.
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. de Bono JS, et al. Among authors: attard g. J Clin Oncol. 2007 Jan 20;25(3):257-62. doi: 10.1200/JCO.2006.07.0888. J Clin Oncol. 2007. PMID: 17235043 Clinical Trial.
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.
Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J. Plummer R, et al. Among authors: attard g. Clin Cancer Res. 2007 Oct 15;13(20):6187-94. doi: 10.1158/1078-0432.CCR-07-0950. Clin Cancer Res. 2007. PMID: 17947486 Clinical Trial.
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Attard G, et al. J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645193 Clinical Trial.
300 results